An oncogenic role of miR-22 was also suggested, for example, in HBV-related HCC, prostate cancer, or chronic lymphocytic leukemia (CLL), where miR-22 upregulation was shown to target important tumor suppressors such as PTEN or ERα [35,36,37]. This evidence concerns the gene PTEN and neoplasm.